Valneva provides clinical and regulatory updates for its covid-19 vaccine vla2001

Saint - herblain ( france), march 2 , 2 02 3 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated covid-19 vaccine, vla2001. as previously announced, valneva will not invest in further development of the vaccine, in the absence of a new partnership1. it is, however, completing remaining clinical studies and submissions as agreed with regulators.
VALN Ratings Summary
VALN Quant Ranking